Influenza A virus subtype H3N2 (also H3N2) is a subtype of viruses that cause influenza (flu). H3N2 viruses can infect birds and mammals. In birds, humans, and pigs, the virus has mutated into many strains. H3N2 is increasingly abundant in seasonal influenza, which kills an estimated 36,000 people in the United States each year.
A recent study published in Viruses reviewed the characteristics of neuraminidase with emphasis on the development of NA-based universal influenza vaccines.
The weekly FluView Report mentions that the number of influenza cases seems to be declining in some areas in the United States. However, the overall seasonal influenza activity remains high.
In a new study, researchers reported the first H5N3 infection in a captive Emperor Tamarin.
Researchers estimated influenza VE in patients aged ≥6 months seeking outpatient care for ARI due to the influenza A(H3N2) virus between October 2021 and April 2022 in the United States (US).
Researchers detected a swine influenza A virus (IAV)-infected patient in routine surveillance at the National Influenza Center in Denmark. The detected influenza variant appeared distinct from any variant found previously in Denmark.
The latest WHO report updated up to 30 October 2022 has data categorized by influenza transmission zones, i.e., countries/regions with similar influenza transmission patterns.
Researchers proposed that vaccines targeting the immunosubdominant yet conserved hemagglutinin (HA) stem could trigger broadly neutralizing antibodies (bnAbs) against influenza A viruses.
The rate of influenza cases throughout the U.S. continues to rise.
New research presented this week at ACR Convergence 2022, the American College of Rheumatology's annual meeting, showed that discontinuing methotrexate for one week after seasonal influenza vaccination provided the same seroprotection as a two-week discontinuation period in patients with rheumatoid arthritis.
Influenza infection and hospitalization rates continue to increase at an alarmingly fast and early rate this year.
Researchers evaluated the impact of the timing of influenza (flu) vaccine administration on vaccine-induced immunity against infection.
A recent study published in the Pulmonary Pharmacology & Therapeutics journal described different inhalation therapeutic agents for treating respiratory viral infections like coronavirus disease 2019 (COVID-19).
In a new study, researchers calculated the decrease in vaccine effectiveness due to repeated influenza vaccinations.
Shinhye et al. look into the impact of COVID-19 measures on influenza circulation in Canada between 2020 and 2022 and the vaccine effectiveness against late-season influenza illness due to A(H3N2) in 2022.
In a new study, researchers conducted a community-based prospective cohort study in Managua, Nicaragua, before the winter season when influenza A (H3N2) cases surge in the Northern Hemisphere.
In a new study, researchers developed a recombinant bivalent vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and influenza viruses.
Researchers found proof of negative repercussions of immune history in SARS-CoV-2 infection.
A new universal flu vaccine protects against diverse variants of both influenza A and B viruses in mice, according to a new study by researchers in the Institute for Biomedical Sciences at Georgia State University.
Researchers explored how the natural alterations inside the SARS-CoV-2 glycan barrier affect the spike protein dynamics.
A new study has explored the entrapment efficacy of CTB-ACE2 chewing gum against different strains of SARS-CoV-2.